Compare BIO-TECHNE Corp (TECH) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Block Inc — how do they compare? BIO-TECHNE Corp trades at $72.31 (market cap $11.24B), while Block Inc trades at $78.49 (market cap $47.45B). The key difference: Block Inc is far larger — about 4.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| TECH | XYZ | |
|---|---|---|
Market Cap | $11.24B | $47.45B |
Sector | Health | Technology |
52-Week High | $72.29 | $84.64 |
52-Week Low | $43.31 | $49.04 |
Enterprise Value | $11.32B | $42.35B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
XYZ trades at $79.00, down slightly by 0.03% with a bullish technical signal. The company reported strong Q2 2026 results with EPS of $1.02 beating estimates by 17%, driven by 25% gross profit growth and raised 2026 guidance. Despite a high P/E ratio of 141, analyst consensus remains strongly bullish with a $99.17 price target representing 25% upside potential. Recent institutional buying and positive earnings momentum support the bullish case.
The outlook remains positive with strong execution in Cash App and Square segments, though elevated valuation and recent CFO stock sales warrant caution. Key risks include competitive pressures and execution of AI-driven restructuring. The stock presents growth potential but requires monitoring of margin sustainability and debt levels that have increased to 21.86% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
